Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-09-20 EDT			5-day change	1st Jan Change
889.50 ^DKK	-3.10%		-1.28%	+138.34%

09-18	Zealand Pharma A/S Presents at 2024 Cantor Fitzgerald Global Healthcare Conference, Sep-18-2024 09:10 AM
09-09	Zealand Pharma's Weight Management Drug Shows Positive Topline Results in Early-stage Trial	MT

Zealand Pharma A/S(CPSE:ZEAL) added to OMX Copenhagen 20 Index

June 23, 2024

Zealand Pharma A/S Added to OMX Copenhagen 20 Index.

Latest news about Zealand Pharma A/S

Zealand Pharma A/S Presents at 2024 Cantor Fitzgerald Global Healthcare Conference, Sep-18-2024 09:10 AM	09-18
Zealand Pharma's Weight Management Drug Shows Positive Topline Results in Early-stage Trial	09-09	MT
Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight	09-09	MT
Zealand Pharma Announces Positive Topline Results from 13-Week Phase 1B Multiple Ascending Dose Clinical Trial with Glp-1/Glp-2 Receptor Dual Agonist Dapiglutide	09-09	CI
Which way to go?	08-16
Danske Bank Downgrades Zealand Pharma to Sell	08-16	MT
Zealand Pharma A/S, Q2 2024 Earnings Call, Aug 15, 2024	08-15
Zealand Pharma: increased investments, but widened losses	08-15	CF
Zealand Pharma seeks big pharma partners for obesity drug candidate	08-15	RE
Zealand Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-15	CI
Global markets live: Starbucks, J&J, On Holding, GM, Pandora...	08-13
Zealand Pharma Names Chief Commercial Officer	07-30	MT
Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024	07-29	CI
Carnegie Group Downgrades Zealand Pharma to Hold from Buy, Lifts PT	07-08	MT
Would you like some more inflation?	06-28
Zealand Pharma Upsizes Directed Share Offering to $1 Billion Amid Strong Demand	06-26	MT
Zealand Pharma A/S(CPSE:ZEAL) added to OMX Copenhagen 20 Index	06-23	CI
Zealand Pharma shares soar on obesity results	06-21	CF
Europe's STOXX 600 falls as tech, banks drag	06-21	RE
European shares open lower as tech losses weigh	06-21	RE
Zealand Pharma Says Petrelintide Drug Reduces Weight in Phase 1b Study	06-21	MT
Zealand Pharma A/S - Special Call	06-20
Zealand Pharma's drug reduces weight by 8.6% in early-stage study	06-20	RE
Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide	06-20	CI
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup	06-17	DJ

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Employees

288

Sector

Biotechnology & Medical Research

Calendar

2024-11-07 - Q3 2024 Earnings Release

More about the company